CAM-cytarabine, aclarubicin plus macrophage colony-stimulating factor in the treatment of acute myelogenous leukemia with trilineage dysplasia: usefulness of in vitro apoptosis in leukemic cells

Leuk Lymphoma. 2001 Jul;42(3):387-91. doi: 10.3109/10428190109064595.

Abstract

A 67-year-old woman was treated for acute myelogenous leukemia with trilineage dysplasia (AML-TLD) by combination chemotherapy with cytarabine, aclarubicin plus macrophage colony-stimulating factor (M-CSF) (referred to as CAM therapy). Complete remission was achieved after two courses of CAM therapy. After coculture of her bone marrow mononuclear cells with M-CSF in vitro, differentiation of leukemic cells into macrophages with apoptotis was observed. This case confirms an earlier report that an effect of M-CSF inducible by differentiation with apoptotic phenomena, against human leukemic cells was shown both in vitro and in vivo when achieving complete remission.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antigens, CD / analysis
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Marrow Cells / pathology
  • Coculture Techniques
  • Female
  • Humans
  • Immunophenotyping
  • Leukemia, Myelomonocytic, Acute / drug therapy*
  • Leukocytes, Mononuclear / pathology
  • Macrophage Colony-Stimulating Factor / therapeutic use*
  • Time Factors
  • Treatment Outcome

Substances

  • Antigens, CD
  • Macrophage Colony-Stimulating Factor